BioNTech SE: BioNTech Announces Second Quarter Financial Results and Corporate Update

Second quarter revenues of €3.2 billion1, net profit of €1.7 billion and fully diluted earnings per share of €6.45 ($6.872) as well as first half 2022 revenues of €9.6 billion, net profit of €5.4 billion

Related Keywords

Japan ,United States ,Hong Kong ,Argentina ,Rwanda ,South Africa ,Ukraine ,Germany ,Kigali ,W09 ,Nepal ,Ecuador ,Uruguay ,Chile ,Peru ,South Korea ,Switzerland ,Turkey ,Federal Republic Of Germany ,American ,Matinas Biopharma ,Regeneron Libtayo ,Helmut Jeggle ,Fosun Pharma ,Sylke Maas ,Rudolf Staudigl ,Anja Morawietz ,Genmabas Genmab ,Biontech Ribomab ,Jens Holstein ,Ugur Sahin ,Matinas Biopharma Holdings Inc ,Genentech ,American Society Of Clinical Oncology ,German Central Bank Deutsche Bundesbank ,Influenza Vaccine Program ,Nasdaq ,Vaccine Program ,Development Expenses ,Pfizer ,Vp Corporate Communications ,Pfizer Inc ,European Union ,Regeneron Pharmaceuticals Inc ,Association For Cancer Immunotherapy ,Shanghai Fosun Pharmaceutical Group Co Ltd ,European Commission ,Drug Administration ,Genentech Inc ,American Association For Cancer Research ,Biontech Group ,Institutional Shareholder Services ,African Union ,European Medicines Agency ,Use Authorization ,Year Expenses ,Year Tax Assumptions ,Shanghai Fosun Pharmaceutical ,Administrative Expenses ,Cash Deposits ,Trade Receivables ,Annual Report ,Quarterly Report ,Current Report ,German Central Bank ,Deutsche Bundesbank ,Member State ,Developed Markets ,Emerging Markets ,Intl Developed ,Conditional Marketing Authorization ,Biologics License Application ,Regeneron Pharmaceuticals ,Clinical Oncology ,American Association ,Cancer Research ,Priority Medicines ,Federal Republic ,Matinas Biopharma Holdings ,Supervisory Board ,Annual General Meeting ,Depositary Shares ,Investor Relations ,Private Securities Litigation Reform Act ,Condensed Consolidated Statements ,Biontech ,Nnounces ,Second ,Quarter ,Financial ,Results ,Corporate ,Update ,